Analyzing...
Loading company...
“Operates in Pharmaceuticals — Formulations & API.”
₹3 Cr revenue.
COGS 99.2%, employees 25.5%.
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹3 Cr +541.6% | ₹0.41 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Income | ₹9 Cr +15.4% | ₹7 Cr +74.3% | ₹4 Cr -36.3% | ₹7 Cr -75.2% | ₹27 Cr +872.3% | ₹3 Cr -5.7% | ₹3 Cr |
| Total Income | ₹11 Cr +43.0% | ₹8 Cr +83.9% | ₹4 Cr -36.3% | ₹7 Cr -75.2% | ₹27 Cr +872.3% | ₹3 Cr -5.7% | ₹3 Cr |
| COGS | ₹3 Cr +552.3% | ₹0.40 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹4 Cr +90.3% | ₹2 Cr +23.8% | ₹2 Cr -36.8% | ₹3 Cr +33.4% | ₹2 Cr +4.9% | ₹2 Cr -8.5% | ₹2 Cr | |
| Profit Before Tax | ₹7 Cr +24.9% | ₹6 Cr +125.7% | ₹3 Cr -35.9% | ₹4 Cr -84.2% | ₹25 Cr | ₹0.79 Cr +2.2% | ₹0.78 Cr |
| ₹2 Cr +26.7% | ₹1 Cr +14.4% | ₹1 Cr +21.8% | ₹1 Cr +67.9% | ₹0.62 Cr +61.7% | ₹0.38 Cr -18.5% | ₹0.47 Cr | |
| Net Profit | ₹5 Cr +24.3% | ₹4 Cr +239.8% | ₹1 Cr -56.9% | ₹3 Cr -88.1% | ₹24 Cr | ₹0.41 Cr +34.2% | ₹0.31 Cr |
| Other Comprehensive Income | (₹2 Cr) ↓ Decline | ₹6 Cr ↑ Recovery | (₹2 Cr) ↓ Decline | ₹0.49 Cr -75.8% | ₹2 Cr ↑ Recovery | (₹2 Cr) ↓ Decline | ₹0.86 Cr |
| EPS | ₹4.27 | ₹3.43 | ₹1.01 | ₹2.34 | ₹19.73 | ₹0.33 | ₹0.25 |
| Diluted Shares | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bakkt Opco Holdings, LLC
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pishu V Chainani
Please refer the attached intimation.
Please refer the attached intimation.
Please refer the attached intimation.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td>...
Please refer the attached intimation
Please refer the attached intimation.
Please refer the attached intimation.
Please refer the attached intimation.
Transchem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 ,inter alia, to consider and approve Un-Audited Financial Results of .... Transchem ...
Please refer the attached intimation.
Please refer the attached intimation.
Please refer the attached intimation.
Please refer the attached intimation.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
No dividend history available for this company.